Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 2Colorectal Neoplasms 2Tuberous Sclerosis 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pediatric Solid Tumor 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphangioleiomyomatosis 1Histiocytosis, Non-Langerhans-Cell 1Histiocytosis, Langerhans-Cell 1HER2-positive Breast Cancer 1Early Detection of Cancer 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Castleman Disease 1Breast Screening 1Breast Neoplasms, Male 1Brain Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

pertuzumab 5Trastuzumab 5Docetaxel 3tucatinib 2pyrotinib 1atezolizumab 1Paclitaxel 1Neoadjuvant Therapy 1Injections 1Genetic Testing 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Genetic Testing × 90 days × Clear all
NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

Recruiting
9,000 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡